The antiserum was produced against synthesized peptide derived from human VEGFR2 around the phosphorylation site of Tyr1175. AA range:1141-1190

Phospho-Flk-1 (Y1175) Polyclonal Antibody detects endogenous levels of Flk-1 protein only when phosphorylated at Y1175.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KDyIV

KDR FLK1 VEGFR2

Vascular endothelial growth factor receptor 2

KDR ;
FLK1 ;
VEGFR2 ;
Vascular endothelial growth factor receptor 2 ;
VEGFR-2 ;
Fetal liver kinase 1 ;
FLK-1 ;
Kinase insert domain receptor ;
KDR ;
Protein-tyrosine kinase receptor flk-1 ;
CD antigen CD309

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009],

Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,Function:Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.,similarity:Contains 1 protein kinase domain.,similarity:Contains 7 Ig-like C2-type (immunoglobulin-like) domains.,subunit:Interacts with MYOF (By similarity). Interacts with SHB; upon VEGF activation. Interacts with HIV-1 Tat.,

Cell junction . Endoplasmic reticulum . Cell membrane . Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). .; [Isoform 1]: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.; [Isoform 2]: Secreted .; [Isoform 3]: Secreted.

>>EGFR tyrosine kinase inhibitor resistance ;
>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>Calcium signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>VEGF signaling pathway ;
>>Focal adhesion ;
>>Proteoglycans in cancer ;
>>Fluid shear stress and atherosclerosis